On June 17, 2026 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its team will be attending and participating at the BIO 2026 International Convention taking place June 22-25, 2026 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In attendance from Genprex’s executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. Throughout the duration of the conference, Mr. Gallagher will be available in-person to conduct one-on-one meetings with industry groups to provide an overview of the Company’s gene therapies for cancer and diabetes.
For those interested in meeting with Mr. Gallagher or other members of Genprex’s management team, please request a meeting through the BIO Partnering Portal or by contacting Investor Relations at [email protected].
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
(Press release, Genprex, JUN 17, 2026, View Source [SID1234668775])